证券日报网讯 12月30日，开立医疗发布公告称，公司2025年第二次临时股东大会审议通过《关于取消 监事会、修订并办理工商变更登记的议案》等多项议案。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article highlights that Weisi Medical has developed a comprehensive product matrix of rehabilitation robots that covers both upper and lower limbs, integrating various therapeutic technologies [2] - The company aims to provide high-quality solutions for rehabilitation needs, specifically targeting neurological, motor, critical care, and chronic diseases in the elderly [2] - Weisi Medical's approach focuses on meeting the precise demands of improvement-oriented rehabilitation through advanced technology [2]

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Kaili Medical (300633) as of December 30, 2025, showing a slight decline in stock price and mixed capital flow [1][2]. - As of December 30, 2025, Kaili Medical's stock closed at 26.2 yuan, down 0.49%, with a turnover rate of 0.8% and a trading volume of 34,600 hands, resulting in a transaction amount of 90.73 million yuan [1]. - The capital flow data indicates a net inflow of 9.66 million yuan from main funds, accounting for 10.65% of the total transaction amount, while retail investors experienced a net outflow of 5.95% [1]. Group 2 - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year, but a significant decline in net profit by 69.25% to 33.51 million yuan [2]. - The third quarter of 2025 saw a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year, but a net loss of 13.52 million yuan, reflecting a 78.05% increase in losses compared to the previous year [2]. - The company has a debt ratio of 24.22%, with an investment income of 2.08 million yuan and financial expenses of -38.30 million yuan, while maintaining a gross profit margin of 60.36% [2].

格隆汇12月30日｜国家药监局12月30日在北京召开深化医疗器械警戒试点工作推进会。会议听取了第一 批试点省份工作汇报，研究部署进一步深化试点工作的具体措施。国家药监局党组成员、副局长徐景和 出席会议并讲话。会议要求，要深入贯彻落实党的二十大和二十届历次全会精神，深刻领会深化医疗器 械警戒试点工作的重要意义；要明确各方责任，落实试点工作任务，强化制度和运行机制建设；要完善 平台和体系，推进"一体两翼"建设，提升警戒能力；要充分利用AI等技术，强化科技赋能，快速识别风 险信号，做好风险处置。 ...

计，可集成至直径小至300微米的商用微导管中，实现跨越40倍范围的连续刚度调节。通过建立描述其力 学行为的理论模型，实现对Helixoft微导管运动姿态的精确预测。此外，Helixoft微导管具备良好的功能扩 展性，不仅支持多节段分布式、相互独立的刚度调节，还可集成微型摄像探头、电极或激光光纤等模块， 为实时成像、组织消融和多模态微创介入操作提供支持。在多例活体动物支气管模型中，研究团队在 Helixoft系统中集成了微型成像器件，并结合临床影像设备与自主搭建的导管推进机构，开展了基于双模 态影像引导的磁控导航与靶向药物转运实验。通过血液炎症反应检测和组织学分析等系统性评估，验证了 该系统在体内应用中的可行性与安全性。同时，还完成了输卵管离体器官模型中精准取样演示。 在支气管、脑血管、输卵管等狭窄而曲折的自然腔道中开展微创介入手术，始终是临床实践中的重大 挑战。理想的介入器械需要在不同操作阶段实现可控的力学响应：一方面，具备足够的柔顺性，以安 全穿行于分叉和弯曲的腔道结构；另一方面，在相对笔直的腔道或抵达目标区域时保持必要的刚度， 以避免导管打卷并确保稳定操作。然而，现有微导管的力学性能大多在制造阶段便已固化 ...

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Kangtong Medical (301515) as of December 30, 2025, showing a decline in stock price and mixed capital flow [1][2] - Kangtong Medical reported a main revenue of 344 million yuan for the first three quarters of 2025, representing a year-on-year decrease of 30.06% [2] - The company experienced a net profit loss of 10.21 million yuan for the same period, with a significant year-on-year decline of 150.92% [2] Group 2 - In Q3 2025, Kangtong Medical's quarterly main revenue was 79.12 million yuan, reflecting a year-on-year increase of 42.81% [2] - The company's net profit for Q3 2025 was a loss of 1.80 million yuan, down 138.94% year-on-year [2] - The debt ratio of Kangtong Medical stands at 40.94%, with a gross profit margin of 22.45% [2]

该股主要指标及行业内排名如下： 证券之星消息，截至2025年12月30日收盘，蓝帆医疗(002382)报收于5.51元，下跌1.25%，换手率 0.67%，成交量6.73万手，成交额3729.43万元。 12月30日的资金流向数据方面，主力资金净流入91.51万元，占总成交额2.45%，游资资金净流入97.56 万元，占总成交额2.62%，散户资金净流出189.07万元，占总成交额5.07%。 近5日资金流向一览见下表： 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 蓝帆医疗2025年三季报显示，前三季度 ...

证券之星消息，截至2025年12月30日收盘，春立医疗(688236)报收于22.95元，上涨0.88%，换手率 0.66%，成交量1.9万手，成交额4396.53万元。 该股主要指标及行业内排名如下： 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比上升109.51%；单季度归母净利润7706.19万元，同比上升531.12%；单季度扣非 净利润7451.86万元，同比上升439.4%；负债率15.65%，投资收益321.7万元，财务费用-972.34万元，毛 利率67.27%。春立医疗（688236）主营业务：植入性骨科医疗器械的研发、生产与销售。 该股最近90天内共有9家机构给出评级，买入评级8家，增持评级1家；过去90天内机构目标均价为 31.8。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主 ...

（文章来源：证券日报） 证券日报网讯 12月30日，英科医疗发布公告称，公司于2025年12月30日召开第四届董事会第十三次会 议，审议通过了《关于拟购买董事、高级管理人员责任险的议案》，公司拟为公司及全体董事、高级管 理人员购买责任保险。本事项尚需公司股东会审议通过。 ...

Core Viewpoint - Mingde Biological plans to acquire 100% equity of Wuhang Bikaier Rescue Supplies Co., Ltd. from Bluefan Medical, which is expected to constitute a significant asset restructuring [1] Group 1: Transaction Details - The transaction is currently in the planning stage, with a framework agreement reached between Mingde Biological and Bluefan Medical [1] - The acquisition will be conducted in cash and will not involve a restructuring listing or related party transactions [1] - The final transaction terms will be based on a formal acquisition agreement signed by both parties [1] Group 2: Company Background and Financials - Bikaier, a wholly-owned subsidiary of Bluefan Medical, is a leading company in emergency rescue products, with a strong market presence across various sectors [1][2] - In the first half of 2025, Bikaier achieved revenue of 75.8 million yuan and a net profit of 7.5 million yuan, with total assets of 228 million yuan, showing stable performance compared to the previous year [2] Group 3: Strategic Implications - Mingde Biological views this acquisition as a strategic move to focus on its critical care business segment [2] - The integration is expected to extend Mingde Biological's critical care diagnostic services from medical institutions to industrial and household scenarios, creating a "diagnosis-protection-treatment" ecosystem [3] - The company aims to enhance its asset quality and profitability while strengthening its market position and competitive edge in the critical care sector [3]